Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telomelysin (OBP-301) + Pembrolizumab in Esophagogastric Adenocarcinoma
NCT03921021Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- May 2019
- Primary completion
- Jun 2023
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of suratadenoturev in Esophago-Gastric Adenocarcinoma, sponsored by Weill Cornell Medicine. Primary endpoint: Overall Response Rate at 1 year. Started May 2019; status: completed.
02
Drugs
suratadenoturev
03
Conditions
Esophago-Gastric Adenocarcinoma
Beyond the preview
Go deeper on NCT03921021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03921021.